Risk stratification and medical therapy of pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability over the past 15 years of multiple drugs interfering with the endothelin, nitric oxide and prostacyclin pathways. The recent progress observed in medical therapy of PAH is not, therefore, related to th...

Descripción completa

Detalles Bibliográficos
Autores principales: Galiè, Nazzareno, Channick, Richard N., Frantz, Robert P., Grünig, Ekkehard, Jing, Zhi Cheng, Moiseeva, Olga, Preston, Ioana R., Pulido, Tomas, Safdar, Zeenat, Tamura, Yuichi, McLaughlin, Vallerie V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2019
Materias:
Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351343/
https://www.ncbi.nlm.nih.gov/pubmed/30545971
http://dx.doi.org/10.1183/13993003.01889-2018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351343/
https://www.ncbi.nlm.nih.gov/pubmed/30545971
http://dx.doi.org/10.1183/13993003.01889-2018

Ejemplares similares